Mirikizumab Maintains UC Disease Clearance Over 4 Years in LUCENT-3, With Jean-Frédéric Colombel, MD
Colombel discusses 4-year LUCENT findings showing sustained disease clearance and a favorable long-term safety profile with mirikizumab in UC
Jean-Frédéric Colombel, MD
Advertisement
Jean-Frédéric Colombel, MD, is director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine at Mount Sinai.
Articles by Jean-Frédéric Colombel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
Artificial Intelligence ECG Model Identifies Patients at Higher Risk for Sudden Cardiac Death
2
FDA Approves Risankizumab for Pediatric Psoriasis, Psoriatic Arthritis
3
Centanafadine XR Meets Phase 3b ADHD Endpoint in Adults With Comorbid Anxiety
4
FDA Expands Roflumilast Cream 0.3% Approval for Plaque Psoriasis in Children Aged 2 Years and Older
5